Catalogue number: X2351B
FLAP; Arachidonate 5-lipoxygenase-activating protein; MK 886 binding protein
|Product Type||Blocking Peptide|
Seems to be required for the activation of 5-LO (5-lipoxygenase). Could play an essential role in the transfer of arachidonic acid to 5-LO. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes. Genetic variations in FLAP may be a cause of susceptibility to ischemic stroke [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
Synthetic peptide derived from human FLAP protein.
See vial for concentration
Provided as solution in phosphate buffered saline
For use with FLAP polyclonal antibodies (Cat. No. X2318P & X2350P).
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles
Ship at ambient temperature, freeze upon arrival
Products are stable for one year from purchase when stored properly
1. Dixon, R.A.F., et al. 'Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.; Nature 343:282-284(1990). 2. Helgadottir, A., et al. 'The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.; Nat. Genet. 36:233-239(2004).
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.